Gehirnimplantat und Verwendung davon

Details

Veröffentlichungs-Nr.

EP4799641

Anmeldetag

28. Februar 2025

Veröffentlichung

2. September 2026

Rechtsraum

EP

Abstract

The present invention relates to brain implant for linear release of 5-aminolevulinic acid comprising:a) a core comprising:5-aminolevulinic acid and a core polymer,wherein the core polymer is selected from the group consisting of poly(lactic acid) (PLA), poly(ethylene oxide) (PEO), poly(ethylene glycol) (PEG), and poly(lactic-co-glycolic acid) (PLGA);andb) a shell consisting of an upper membrane, a spacer, and a lower membrane, wherein the upper membrane, the spacer, and the lower membrane each comprise a shell polymer, wherein the shell polymer is poly(lactic acid) (PLA);characterized in thatthe shell polymer is in a range from 20 wt.% to 60 wt.% based on the total weight of the brain implant;andwhen the core polymer is poly(lactic acid) (PLA), poly(ethylene oxide) (PEO), poly(ethylene glycol) (PEG), the core contains 5-aminolevulinic acid in a range from 25 wt.% to 45 wt.%, and the core polymer in a range from 75 wt.% to 55 wt.% based on the total weight of the core;orwhen the core polymer is poly(lactic-co-glycolic acid) (PLGA), the core contains 5-aminolevulinic acid in a range from 65 wt.% to 75 wt.% and the core polymer in a range from 35 wt.% to 25 wt.% based on the total weight of the core;a preparation method of said brain implant,anda medical use thereof, in particular in the prophylaxis and/or treatment of brain cancer.

Anmelder

Firma

JLP Health GmbH

Land

🇦🇹 Österreich